Abilion Medical Systems

Abilion Medical Systems is a private, pre-revenue medical device developer pioneering a novel, non-pharmacological treatment for migraine and other conditions. Its core technology, INMEST, uses gentle mechanical stimulation of intranasal nerves to modulate the autonomic nervous system and influence immune regulation, specifically targeting regulatory T-cells (Tregs). The company is developing a connected system comprising a handheld device, mobile app, and cloud platform to enable monitored home-based treatment, aiming to address the significant unmet needs in migraine care related to drug side effects and poor treatment adherence.

INMEST (Intranasal Mechanical Stimulation): A handheld medical device system for home use that delivers gentle mechanical stimulation to intranasal nerves. It is proposed to modulate the autonomic nervous system and influence immune regulation by activating regulatory T-cells (Tregs), aiming to reduce neuroinflammation and restore physiological balance without drugs or implants.

In migraine, Abilion competes with pharmaceutical prophylactics (CGRP mAbs/gepants, beta-blockers) and other neuromodulation devices (e.g., external trigeminal nerve stimulators, vagus nerve stimulators). Its key differentiator is the proposed intranasal, Treg-focused mechanism and home-use design. In broader immunology, it would face competition from a wide array of biologic and small molecule drugs.